Merck KGaA operates in three main segments: Life Science, Electronics, and Healthcare... Show more
MKKGY moved below its 50-day moving average on July 11, 2025 date and that indicates a change from an upward trend to a downward trend. In of 36 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 63 cases where MKKGY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved below the 0 level on July 14, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on MKKGY as a result. In of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for MKKGY turned negative on July 15, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MKKGY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MKKGY advanced for three days, in of 318 cases, the price rose further within the following month. The odds of a continued upward trend are .
MKKGY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.655) is normal, around the industry mean (62.813). P/E Ratio (21.413) is within average values for comparable stocks, (89.433). Projected Growth (PEG Ratio) (3.091) is also within normal values, averaging (2.987). Dividend Yield (0.014) settles around the average of (0.124) among similar stocks. P/S Ratio (3.108) is also within normal values, averaging (19.385).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. MKKGY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MKKGY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock better than average.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Industry PharmaceuticalsOther
A.I.dvisor indicates that over the last year, MKKGY has been loosely correlated with MKGAF. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if MKKGY jumps, then MKGAF could also see price increases.
Ticker / NAME | Correlation To MKKGY | 1D Price Change % | ||
---|---|---|---|---|
MKKGY | 100% | -0.97% | ||
MKGAF - MKKGY | 49% Loosely correlated | +0.90% | ||
AMPH - MKKGY | 25% Poorly correlated | -3.51% | ||
ZTS - MKKGY | 25% Poorly correlated | -1.79% | ||
SUPN - MKKGY | 25% Poorly correlated | -1.33% | ||
INDV - MKKGY | 24% Poorly correlated | -1.54% | ||
More |